An angiotensin IV-derived molecule studied for HGF/c-Met-linked neuroplasticity.
Also known as: PNB-0408 · N-hexanoic-Tyr-Ile-(6)aminohexanoic amide
Part of the Neuropeptides & signaling cluster
Overview
Dihexa (PNB-0408) is a synthetic angiotensin IV-derived oligopeptide studied as a potentiator of hepatocyte growth factor (HGF) signaling at the c-Met receptor. It is investigated in preclinical cognition and neuroplasticity research and is not an approved therapeutic in Canada.
Source & context
Biological / chemical source: Synthetic modified peptide derived from angiotensin IV
Primary research or clinical context: Research compound; not an approved drug in Canada
Mechanism under study
Dihexa is chemically N-hexanoic-Tyr-Ile-(6)aminohexanoic amide, a stabilized derivative of angiotensin IV. Research reports describe it binding hepatocyte growth factor and enhancing signaling through the c-Met receptor, a pathway linked to synaptogenesis and neuroprotection in laboratory models.
Research context and cautions
Preclinical studies have described high potency in neurotrophic assays, fueling nootropic interest online. A related phosphate prodrug, fosgonimeton, has been evaluated in clinical trials for neurodegenerative disease. Dihexa itself remains investigational, and popular claims outpace the available human evidence.
FAQ about Dihexa
What is Dihexa?+
Dihexa (PNB-0408) is a synthetic angiotensin IV-derived oligopeptide studied as a potentiator of hepatocyte growth factor (HGF) signaling at the c-Met receptor. It is investigated in preclinical cognition and neuroplasticity research and is not an approved therapeutic in Canada.
Is Dihexa an approved medicine?+
Dihexa is discussed here as a research / educational topic. Research compound; not an approved drug in Canada. This is not medical advice.
What is the typical length of Dihexa?+
Dihexa is not a classic amino-acid chain peptide in the same sense; see the profile for classification details.